Lung Cancer | Specialty

Osimertinib As Frontline Therapy in EGFR-Positive NSCLC

July 26th 2018

Frontline Brigatinib Improves PFS in ALK+ NSCLC

July 25th 2018

Brigatinib reduced the risk of disease progression or death versus crizotinib in adult patients with locally advanced or metastatic ALK-positive non–small cell lung cancer who had not received a prior ALK inhibitor.

Targeted Therapies Emerging for Less-Common NSCLC Subtypes

July 25th 2018

Jessica Bauman, MD, addresses current and emerging therapeutic options for patients with BRAF, ROS1, and RET abnormalities in non–small cell lung cancer.

Biomarkers for Frontline Immunotherapy Pose Obstacles in NSCLC

July 25th 2018

John A. Kosteva, MD, discusses the adoption of immunotherapy into the treatment paradigm for patients with non–small cell lung cancer.

Langer Highlights the Impact of Chemoimmunotherapy in NSCLC

July 24th 2018

Although impressive single-agent data have been seen with agents such as pembrolizumab (Keytruda) versus chemotherapy in a high–PD-L1 population, the combination of PD-L1 inhibitors and chemotherapy may prove to be beneficial in a broader group of patients.

Palliative Thoracic EBRT With Concurrent Chemotherapy Is an Option for Incurable NSCLC

July 23rd 2018

A review of available evidence has led the American Society for Radiation Oncology to issue a strong recommendation for use of concurrent chemotherapy with thoracic external beam radiation therapy in a subset of patients with incurable stage III non–small cell lung cancer.

Dr. Agarwala on Impact of Combining Entinostat with Pembrolizumab

July 20th 2018

Sanjiv S. Agarwala, MD, chief of medical oncology and hematology, St. Luke’s Cancer Center, professor of medicine, Temple University School of Medicine, discusses the impact of combining entinostat with pembrolizumab (Keytruda) across a number of tumor types.

Dr. Horn on Selecting Inhibitors for ALK+ NSCLC

July 20th 2018

Leora Horn, MD, associate professor of medicine (hematology and oncology), assistant director, educator development program, clinical director, Thoracic Oncology, medical oncologist, Vanderbilt-Ingram Medical Center, discusses selecting the necessary inhibitor for patients with ALK-positive non-small cell lung cancer.

Dr. Shunyakov on the Impact of Next-Generation Sequencing in Oncology

July 20th 2018

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses the impact of next-generation sequencing (NGS) in oncology.

Atezolizumab Regimen Extends PFS in Frontline Nonsquamous NSCLC

July 19th 2018

Adding atezolizumab to pemetrexed and cisplatin or carboplatin in the frontline setting reduced the risk of disease progression or death versus chemotherapy alone in patients with advanced nonsquamous non–small cell lung cancer, according to findings from the phase III IMpower132 study.

West Coast Study Rates Cancer Centers by Cost and Quality

July 17th 2018

In a groundbreaking study of costs and quality of cancer care among cancer clinics in the state of Washington, investigators found wide disparity in end-of-life care, suggesting that improvements in cost and quality could be attained if treatment centers share information on what works and endeavor to improve.

Ramalingam Reflects on Recent Advances in SCLC

July 17th 2018

Suresh A. Ramalingam, MD, reflects on recent data in small cell lung cancer and what is on the horizon in the landscape.

Dr. West Discusses Latest Immunotherapy Findings in Lung Cancer

July 17th 2018

H. Jack West, MD, medical director of thoracic oncology, Swedish Cancer Institute of Swedish Medical Center, discusses the latest immunotherapy findings for lung cancer treatment.

Progress Continues in EGFR+ NSCLC Paradigm

July 16th 2018

Charu Aggarwal, MD, discusses the latest developments in EGFR-mutant lung cancer.

Levy Highlights Benefits, Limitations of Liquid Biopsies in NSCLC

July 16th 2018

Benjamin P. Levy, MD, highlights the pros and cons of the different platforms for circulating tumor DNA detection, as well as the benefits and limitations of liquid biopsies.

State of Immunotherapy Continues to Shift in NSCLC

July 13th 2018

Liza C. Villaruz, MD, addresses the immunotherapy clinical trials that have informed the treatment of patients with NSCLC and the current state of biomarkers in the field.

Dr. Ganti on Lung Cancer Abstracts From the 2018 ASCO Annual Meeting

July 12th 2018

Apar Kishor Ganti, MD, professor of internal medicine, Division of Oncology/Hematology, University of Nebraska Medical Center, discusses lung cancer abstracts that were presented at the 2018 ASCO Annual Meeting.

Dr. Herbst on the Bevacizumab Biosimilar in Lung Cancer

July 11th 2018

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the bevacizumab (Avastin) biosimilar in lung cancer.

Advancing the Treatment of Nondriver Metastatic NSCLC

July 10th 2018

Sequencing Through Multiple Relapses in Nondriver mNSCLC

July 10th 2018